Abstract Successful translation of medical devices from the bench to the bedside is conditioned by the accurate estimation of market opportunities. Because market conditions can change significantly over time, this assessment is challenging in the early stages of technological development. In this study a qualitative analysis of market trends and regulatory frameworks was conducted to assess how transient market conditions influence the development and distribution of nanomedical technologies, using nanotechnologies developed for COVID-19 as the example. The findings demonstrate that the unpredictable nature of the COVID-19 pandemic has led to a volatile market for nanomedical solutions, discouraging private sector investment and contributing to growing disparities in resource allocation. Because access to these nanomedical technologies has been determined more by financial and geopolitical factors than by genuine medical need, it is argued that a more regulated market is necessary to ensure fair distribution of the products of nanomedical R&D. Policies should prioritize equitable access based on medical necessity rather than economic privilege to support the sustainable development of future nanotechnologies. To emphasize the necessity of humanizing sciences underlying the development of new medical technologies, these arguments are provided from a personal perspective, in the context of a 180-mile commute the author has taken weekly, for many years, to teach this subject in a higher education setting. To additionally challenge the linear flow and impersonal didactics of papers from the relevant technical genre, the discussion swings between topics, following a natural stream of thought, arguing concordantly in favor of the adoption of the same type of freedom, intuitive and improvisatory, in every aspect of human expressions and inquiries about the physical world.
Vuk Uskoković (Sat,) studied this question.